@article{d71fde0dedb94b26850a60008cc92765,
title = "Beyond chemotherapy: Targeted therapies in ovarian cancer",
abstract = "Ovarian cancer is the leading cause of death from gynaecological malignancies in the Western world. Despite the evolution of surgical techniques and meticulously designed chemotherapy regimens, relapse remains almost inevitable in patients with advanced disease. In an age when great advances have been made in understanding the genetics and molecular biology of this heterogeneous disease, it is likely that the introduction of novel targeted therapies will have a major impact on the management of ovarian cancer. Importantly, such strategies might allow selection of treatments based on the molecular characteristics of tumours and bring us closer to an era of personalized medicine.",
author = "Yap, {Timothy A.} and Carden, {Craig P.} and Kaye, {Stan B.}",
note = "Funding Information: The Drug Development Unit is supported by Cancer Research UK through a programme grant to the Section of Medicine, Institute of Cancer Research, and through an Experimental Cancer Medical Centre (ECMC) grant (C51/A7401). It is also supported by the Department of Health through the ECMC grant and as part of the National Institutes of Health Research Biomedical Research Centre at the Royal Marsden Hospital. T.A.Y., C.P.C. and S.B.K. are employees of The Institute of Cancer Research. T.A.Y. and C.P.C. are Cancer Research UK Clinical Research Fellows (C309/A8274 and C1178/A7851). We would like to thank L. Readings for her invaluable assistance with the preparation of the manuscript.",
year = "2009",
month = mar,
day = "1",
doi = "10.1038/nrc2583",
language = "English (US)",
volume = "9",
pages = "167--181",
journal = "Nature Reviews Cancer",
issn = "1474-175X",
publisher = "Nature Publishing Group",
number = "3",
}